When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CPHRF - Aclaris Therapeutics: New Data From Phase 3 Of Development Soon
Companhia Siderurgica Paulista Nova Cosipa
With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics (ACRS) is a name to be followed carefully. The Phase 3 trial is estimated to be completed on January 15, 2020. With that said, the company’s cash burn rate is very significant. We would sell after the FDA decision if the decision is not favorable. Notice that the dilution risk on Aclaris is too high.
Business Model And Lead Product Candidate A-101
Aclaris Therapeutics develops treatments for dermatological and immuno-inflammatory diseases.